Cardiovascular Outcomes Update in SGLT-2 Inhibitors
Patients with diabetes, especially advanced diabetes, typically have comorbid cardiovascular disease. Current practice is to manage hyperglycemia via insulin, metformin, or selection of additional agents based on cost, patient preference, and side effect profiles. Furthermore, the cardiovascular disease is managed via the ACEi/ARBs, beta-blockers, calcium channel blockers and other cardiovascular agents. SGLT-2 inhibitor manufacturers recently published data to support the use of SGLT-2 inhibitors in cardiovascular disease with or without diabetes. This CE presentation will present new and existing data for the use of SGLT-2 inhibitors in cardiovascular disease. This will help pharmacy staff and health care professionals to make appropriate decisions for their patients regarding their chronic disease management.
Target Audience
- Pharmacists
- Pharmacy technicians
Learning Objectives
Pharmacist learning objectives
- Describe cardiovascular mechanisms of SGLT-2 inhibitors
- Review and discuss recent cardiovascular outcomes from SGLT-2 trials
- Outline placement of SGLT-2 inhibitors in treatment algorithms
Pharmacy technician learning objectives
- Recognize medications used in diabetes and heart failure
- Describe the role of SGLT-2 medications in diabetes and heart failure
Additional Information
Attachment | Size |
---|---|
![]() | 157.72 KB |
![]() | 125.06 KB |
![](https://continuingeducation.vizientinc.com/sites/default/files/Joint%20Accred%20LOGO.png)
Available Credit
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE - Attendance